{"id":976239,"date":"2026-06-26T16:09:25","date_gmt":"2026-06-26T20:09:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/"},"modified":"2026-06-26T16:09:25","modified_gmt":"2026-06-26T20:09:25","slug":"larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/","title":{"rendered":"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>Webcast on Monday, June 29, 2026, at 7:45 am ET<\/em><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">BALA CYNWYD, Pa., June  26, 2026  (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company\u2019s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich\u2019s ataxia on Monday, June 29, 2026 at 7:45 am ET.<\/p>\n<p align=\"justify\">\n        <strong>Webcast Details<\/strong><br \/>\n        <br \/>To access the webcast on Monday, June 29, 2026, at 7:45 am EDT, please visit this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QiDT3Z_turrFsXBnP_1V1fSinwkLxwLK_DTf2_pph6Xe3ATkC5jyi43P0K7Cd5ECOZs0amcKbCae65x2E3Qj9WfLxUXSdYo_mRsf0BO4uCQ=\" rel=\"nofollow\" target=\"_blank\">link<\/a> to the event. Following the live event, an archived webcast will be available on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jEmSaMaUa_oOTu4JsXXzdl9o-Mu9OTTIM0DgrozM8swlSdyAl0fgAyQe7zuy1Xi-n5cAINcw16SxGKwWuY7em92DdbpoiS5KVJ0IpN01M2jVmmvZQHYJIaTMRw7H6NgRPS2jqlRRMDP7ckn6kWS90I-wAVX-v-KcOXlHc2oc9zA=\" rel=\"nofollow\" target=\"_blank\">Events &amp; Presentations<\/a>\u201d page of the Larimar website.<\/p>\n<p align=\"justify\">\n        <strong>About Larimar Therapeutics<\/strong><br \/>\n        <br \/>Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, nomlabofusp, is being developed as a potential treatment for adults and children with Friedreich&#8217;s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lue3C59PLfwjntsgp31lXvA8ybg8x6nXUqnNNy3gtNuOcJMOgQWziKiUlwN0himG2s8ILNnFNYjXScgYSYxIFj1BwFZKR6P9jtLBoN4SJ-8=\" rel=\"nofollow\" target=\"_blank\">https:\/\/larimartx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements that are based on Larimar\u2019s management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar\u2019s ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar\u2019s planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding the timing of the BLA submission, the expectations of the timing of, and potential for, accelerated approval or accelerated access, time to launch and market and overall development plans and other matters regarding Larimar\u2019s business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.<\/p>\n<p align=\"justify\">In some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ctarget\u201d, \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar\u2019s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA and Larimar\u2019s ability to timely implement the revised dosing regimen in its clinical program for nomlabofusp; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar\u2019s nomlabofusp development strategy; that the FDA may not ultimately agree with Larimar\u2019s rolling BLA submission strategy; Larimar\u2019s ability to submit BLA modules on the intended timelines; Larimar\u2019s ability to realize the benefits of Breakthrough Therapy Designation; the potential impact of public health crises on Larimar\u2019s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar\u2019s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp\u2019s manufacturing process; Larimar\u2019s ability to obtain regulatory approvals for nomlabofusp and future product candidates; the timing of any potential commercial launch of nomlabofusp, if approved; Larimar\u2019s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar\u2019s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar\u2019s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ULC8B47oH2Kp1iNAYZRmpQomoEkacPKAqpmJqyUsGaye1bW-pZiKf5NnQ1_454SfyFRvnTADmImqKKwDnNtJ5Q==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar\u2019s management\u2019s views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Joyce Allaire<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6v1KP92ZFPppedX_CjEuF6HYIh0p6rdGDMojvUJSn415PIIrXmzDxYOKWZHkTU0iOxL9OdrjPbOBNVSCtCmoPq7Qk4jfiiBYmbosWjoplGRjsks-qH8UP0BHxtVRtPUT\" rel=\"nofollow\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a><br \/>(212) 915-2569<\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Michael Celano<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PHnEqXA3DtEbKUzf5iap9lBMA822bj9xO8kSwuXcpCDwGt2kV_eMufjF0Sx8INyH17YA7_T4jjfPSbFdT6vkVOhwrm5ztDDVOgYzTOD5bMM=\" rel=\"nofollow\" target=\"_blank\">mcelano@larimartx.com<\/a><br \/>(484) 414-2715<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2Q5MmEyY2YtNDVjMC00ZmJhLTg4NGQtOWY3YzU2ZWVkYTI0LTUwMDA3Nzg4OS0yMDI2LTA2LTI2LWVu\/tiny\/Larimar-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company\u2019s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich\u2019s ataxia on Monday, June 29, 2026 at 7:45 am ET. Webcast Details To access the webcast on Monday, June 29, 2026, at 7:45 am EDT, please visit this link to the event. Following the live event, an archived webcast will be available on the \u201cEvents &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-976239","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company\u2019s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich\u2019s ataxia on Monday, June 29, 2026 at 7:45 am ET. Webcast Details To access the webcast on Monday, June 29, 2026, at 7:45 am EDT, please visit this link to the event. Following the live event, an archived webcast will be available on the \u201cEvents &hellip; Continue reading &quot;Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T20:09:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia\",\"datePublished\":\"2026-06-26T20:09:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/\"},\"wordCount\":818,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/\",\"name\":\"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==\",\"datePublished\":\"2026-06-26T20:09:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/","og_locale":"en_US","og_type":"article","og_title":"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia - Market Newsdesk","og_description":"Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company\u2019s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich\u2019s ataxia on Monday, June 29, 2026 at 7:45 am ET. Webcast Details To access the webcast on Monday, June 29, 2026, at 7:45 am EDT, please visit this link to the event. Following the live event, an archived webcast will be available on the \u201cEvents &hellip; Continue reading \"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-26T20:09:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia","datePublished":"2026-06-26T20:09:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/"},"wordCount":818,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/","name":"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==","datePublished":"2026-06-26T20:09:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzQwMSM3Njc5NDIzIzUwMDA3Nzg4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-friedreichs-ataxia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=976239"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976239\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=976239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=976239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=976239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}